Certara, INC. (CERT) — SEC Filings

Overview

Certara, INC. (CERT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 3, 2026: Certara, Inc. filed a Definitive Additional Materials (DEFA14A) on April 3, 2026. This filing is related to proxy materials and does not contain specific financial details or proposals, but rather supplementary information for shareholders.

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 2 bullish, 29 neutral. The dominant filing sentiment for Certara, INC. is neutral.

Filing Type Overview

Certara, INC. (CERT) has filed 12 8-K, 1 ARS, 2 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 1 10-K/A, 2 SC 13G, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• 8-K Filing — 8-K · Apr 22, 2026
• ARS Filing — ARS · Apr 3, 2026
• Certara Inc. Files DEFA14A Proxy Materials — DEFA14A · Apr 3, 2026 Risk: low
  Certara, Inc. filed a Definitive Additional Materials (DEFA14A) on April 3, 2026. This filing is related to proxy materials and does not contain specific financ
• Certara, Inc. Files 8-K on Officer/Director Changes — 8-K · Dec 11, 2025 Risk: medium
  Certara, Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 9, 2025. The filing pertains to the departure of directors or cer
• Certara Swings to Profit on Strong Revenue Growth — 10-Q · Nov 6, 2025 Risk: medium
  Certara, Inc. (CERT) reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $4.3
• Certara, Inc. Files 8-K for Material Definitive Agreement — 8-K · Oct 16, 2025 Risk: medium
  On October 16, 2025, Certara, Inc. entered into a material definitive agreement, likely related to financing or debt, as indicated by the filing of a Form 8-K.
• Certara Swings to Profit on Strong Q2 Revenue Growth — 10-Q · Aug 6, 2025 Risk: medium
  Certara, Inc. reported total revenue of $92.3 million for the three months ended June 30, 2025, a 7.3% increase from $86.0 million in the prior-year period. Net
• Certara, Inc. Reports on Shareholder Vote Matters — 8-K · May 22, 2025 Risk: low
  Certara, Inc. filed an 8-K on May 22, 2025, reporting on matters submitted to a vote of its security holders on May 21, 2025. The filing details the company's c
• Certara, Inc. Files Q1 2025 10-Q Report — 10-Q · May 5, 2025 Risk: low
  Certara, Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The filing details its business operations and financ
• Certara, Inc. Files 8-K on Financials and Agreements — 8-K · Apr 14, 2025 Risk: low
  Certara, Inc. filed an 8-K on April 14, 2025, reporting on a material definitive agreement, results of operations, and financial condition. The filing details t
• Certara Files Definitive Proxy Statement for Annual Meeting — DEF 14A · Apr 8, 2025 Risk: low
  Certara, Inc. filed its definitive proxy statement (DEF 14A) on April 8, 2025, for its annual meeting on May 21, 2025. The filing concerns the solicitation of p
• Certara Announces Executive and Director Changes — 8-K · Mar 5, 2025 Risk: medium
  Certara, Inc. announced on March 3, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the e
• Certara, Inc. Files 2024 10-K Report — 10-K · Feb 26, 2025 Risk: medium
  Certara, Inc. filed its 2024 10-K report on February 26, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, he
• Certara, Inc. Files 8-K on Financials — 8-K · Jan 15, 2025 Risk: low
  Certara, Inc. filed an 8-K on January 15, 2025, to report on its results of operations and financial condition. The filing includes financial statements and exh
• Certara, Inc. Files 2023 Annual Report Amendment — 10-K/A · Dec 16, 2024 Risk: low
  Certara, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing, dated December 16, 2024, provides update
• SC 13G Filing — SC 13G · Nov 13, 2024
• Certara, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 6, 2024 Risk: medium
  Certara, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter an
• Certara Appoints New Directors, Adjusts Executive Compensation — 8-K · Oct 16, 2024 Risk: medium
  Certara, Inc. announced on October 16, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
• SC 13G/A Filing — SC 13G/A · Oct 4, 2024
• Certara, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 6, 2024 Risk: medium
  Certara, Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter and first half of the year, detailing financial performan
• Certara, Inc. Changes Fiscal Year End — 8-K · Jul 19, 2024 Risk: low
  Certara, Inc. filed an 8-K on July 19, 2024, reporting a change in its fiscal year end to December 31st, effective July 17, 2024. This filing also includes fina
• Certara, Inc. Files 8-K for Regulatory Disclosures — 8-K · Jul 9, 2024 Risk: low
  Certara, Inc. filed an 8-K on July 9, 2024, to report on Regulation FD disclosures and to file financial statements and exhibits. The filing does not contain sp
• Certara, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jun 26, 2024 Risk: medium
  On June 26, 2024, Certara, Inc. entered into a material definitive agreement related to a direct financial obligation. The company, headquartered in Radnor, PA,
• Certara, Inc. Files 8-K on Shareholder Vote Matters — 8-K · May 23, 2024 Risk: low
  Certara, Inc. filed an 8-K on May 23, 2024, reporting on matters submitted to a vote of security holders on May 21, 2024. The filing details the company's corpo
• Certara, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Certara, Inc. (CERT) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Certara, Inc. filed a 10-Q report for the period ending March 31, 2024. The fi
• Certara, Inc. Files Proxy Statement Supplement — DEFA14A · Apr 12, 2024 Risk: low
  Certara, Inc. has filed a Definitive Additional Materials proxy statement (DEFA14A) on April 12, 2024, supplementing its previous proxy statement. This filing c
• Certara, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 10, 2024 Risk: low
  Certara, Inc. (CERT) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Certara, Inc. will hold its 2024 Annual Meeting of Stockholders on May 21
• Certara, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Certara, Inc. (CERT) filed a Annual Report (10-K) with the SEC on February 29, 2024. Certara, Inc. reported its fiscal year 2023 results on Form 10-K, filed on
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Baillie Gifford Amends Certara Stake, Signals Portfolio Adjustment — SC 13G/A · Jan 30, 2024
  Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 30, 2024, indicating a change in their ownership of Certara,
• BlackRock Discloses Passive Stake in Certara, Inc. (CERT) — SC 13G · Jan 25, 2024
  BlackRock Inc., a major investment firm, filed an SC 13G on January 25, 2024, disclosing its ownership of Certara, Inc. common stock as of December 31, 2023. Th

Risk Profile

Risk Assessment: Of CERT's 24 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Certara, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $315.19M
• Net Income: $4.3M
• EPS: N/A
• Debt-to-Equity: 0.44
• Cash Position: $172.711M
• Operating Margin: 6.4%
• Total Assets: $1.536B
• Total Debt: $293.541M

Key Executives

• Dr. David E. R. Gross
• Ms. Sarah E. Johnson
• Mr. William R. Feehery
• Mr. Jeffrey S. Palmer
• William F. Feehery

Industry Context

Certara operates within the highly competitive life sciences software and services sector, providing critical solutions for drug development, regulatory affairs, and clinical research. Key trends include the increasing complexity of drug discovery, the growing need for data analytics and AI in R&D, and the demand for efficient regulatory submission processes. Companies like Certara are essential partners for pharmaceutical and biotechnology firms navigating these challenges.

Top Tags

corporate-governance (6) · 10-Q (4) · Certara (3) · management-change (2) · Biosimulation (2) · Revenue Growth (2) · Profitability (2) · Healthcare Technology (2) · financial-obligation (2) · quarterly-report (2)

Key Numbers

• Net Income: $4.3M — Swung from a $18.6M loss in 9M 2024 to a $4.3M profit in 9M 2025.
• Total Revenue: $315.19M — Increased 10.68% from $284.787M in 9M 2024 to $315.19M in 9M 2025.
• Income from Operations: $20.18M — Improved significantly from a $7.734M loss in 9M 2024 to a $20.18M gain in 9M 2025.
• Cash and Cash Equivalents: $172.711M — Decreased from $179.183M at Dec 31, 2024, indicating cash usage.
• Net Cash Used in Financing Activities: $59.173M — Primarily due to common stock repurchases and contingent consideration payments.
• Common Stock Repurchase Program: $38.674M — Significant cash outflow for share repurchases in 9M 2025.
• Payments for Business Acquisition Related Contingent Consideration: $13.230M — Cash outflow for acquisition-related payments in 9M 2025.
• Long-term Debt: $290.541M — Net of current portion and debt discount, remains a significant liability.
• Foreign Currency Translation Adjustment: $18.957M — Positive impact on comprehensive income for 9M 2025.
• Quarterly Revenue Growth: 10.33% — Revenue grew from $94.820M in Q3 2024 to $104.616M in Q3 2025.
• Total Revenue (Q2 2025): $92.3M — Increased by 7.3% from $86.0 million in Q2 2024
• Net Income (Q2 2025): $10.5M — Swung from a net loss of $2.1 million in Q2 2024
• Total Revenue (H1 2025): $181.2M — Increased by 7.5% from $168.5 million in H1 2024
• Net Income (H1 2025): $18.7M — Swung from a net loss of $4.5 million in H1 2024
• Interest Expense (Q2 2025): $10.2M — Decreased from $12.5 million in Q2 2024

Related Companies

CTRA

Frequently Asked Questions